Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Equillium, Inc. stock logo
EQ
Equillium
$1.36
+8.8%
$1.82
$0.76
▼
$3.54
N/AN/AN/A345,656 shs
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
C$0.04
C$0.04
C$0.04
▼
C$0.07
C$10.05M2.131199145,506 shs68,000 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Equillium, Inc. stock logo
EQ
Equillium
+1.63%+0.81%-25.15%-46.12%-11.35%
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
0.00%0.00%-12.50%-22.22%-46.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Equillium, Inc. stock logo
EQ
Equillium
$1.36
+8.8%
$1.82
$0.76
▼
$3.54
N/AN/AN/A345,656 shs
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
C$0.04
C$0.04
C$0.04
▼
C$0.07
C$10.05M2.131199145,506 shs68,000 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Equillium, Inc. stock logo
EQ
Equillium
+1.63%+0.81%-25.15%-46.12%-11.35%
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
0.00%0.00%-12.50%-22.22%-46.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Equillium, Inc. stock logo
EQ
Equillium
2.91
Moderate Buy$7.57456.72% Upside
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TMMG, EQ, OOUT, and SPN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/26/2026
Equillium, Inc. stock logo
EQ
Equillium
Reiterated RatingBuy
10/12/2026
Equillium, Inc. stock logo
EQ
Equillium
Initiated CoverageOutperform$6.00
9/21/2026
Equillium, Inc. stock logo
EQ
Equillium
Reiterated RatingSell (D-)
9/4/2026
Equillium, Inc. stock logo
EQ
Equillium
Reiterated RatingBuy$12.00
8/11/2026
Equillium, Inc. stock logo
EQ
Equillium
UpgradeStrong Sell ➝ Hold
(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/AN/A
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
C$21.85M0.46C$0.01 per share5.91C$0.02 per share1.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Equillium, Inc. stock logo
EQ
Equillium
N/A-$0.20N/AN/AN/AN/AN/AN/A11/12/2026 (Estimated)
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
-C$2.10MN/AN/AN/AN/A-8.11%-33.51%-9.21%N/A

Latest TMMG, EQ, OOUT, and SPN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.05N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.0540-$0.04+$0.0140-$0.04N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/A
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
9.16
0.90
2.18

Institutional Ownership

CompanyInstitutional Ownership
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
0.83%

Insider Ownership

CompanyInsider Ownership
Equillium, Inc. stock logo
EQ
Equillium
17.84%
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
32.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
Equillium, Inc. stock logo
EQ
Equillium
14N/A52.10 millionOptionable
Snipp Interactive Inc. stock logo
SPN
Snipp Interactive
5,200287.11 millionN/ANot Optionable

Recent News About These Companies

Snipp Interactive slaat Q2 2026 omzetverwachting
Snipp Interactive overtreft Q2 2026 omzetverwachtingen
Snipp Interactive Inc (SPN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Equillium stock logo

Equillium NASDAQ:EQ

$1.36 +0.11 (+8.80%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 +0.00 (+0.37%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Snipp Interactive stock logo

Snipp Interactive CVE:SPN

C$0.04 0.00 (0.00%)
As of 10/23/2026 02:51 PM Eastern

Snipp Interactive Inc. provides mobile marketing, rebates, and loyalty solutions in the United States, Canada, Ireland, and internationally. The company offers SnippCheck, a receipt processing system that allows brands to execute customized purchase-based promotions and loyalty programs; SnippWin, a promotion and sweepstakes platform provides various promotions from contests and simple sweepstakes to instant win programs and tiered, multi-level games; and SnippLoyalty, an end-to-end real time multichannel SaaS cloud-based customer loyalty program software. It also provides SnippInsights that enables intelligent advertising and marketing decision making; SnippRewards, a rewards platform that offers various rewards, including movie tickets, PayPal, and other money back mechanisms; SnippRebates, a solution that allows brands to set up and manage single-instance or cross-portfolio rebate marketing programs; and Snipp Payments Media Network that allows brands and retailers to reach a bank's customers with offers and promotions. In addition, the company offers sweepstakes services, including strategy, program build, legal compliance administration, omnichannel activation, rewards, fraud management, and customer support. It serves advertising agencies, brands and related marketing, and promotions agencies. Snipp Interactive Inc. is headquartered in Vancouver, Canada.